Independent Research set a €116.00 ($134.88) target price on MorphoSys (ETR:MOR) in a research note released on Tuesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
MOR has been the subject of several other research reports. Royal Bank of Canada set a €130.00 ($151.16) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Friday, August 9th. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Wednesday, August 7th. Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the stock a neutral rating in a research report on Wednesday, August 7th. Berenberg Bank set a €150.00 ($174.42) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Monday, August 5th. Finally, Deutsche Bank set a €133.00 ($154.65) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of €118.56 ($137.86).
MOR opened at €108.90 ($126.63) on Tuesday. MorphoSys has a twelve month low of €76.45 ($88.90) and a twelve month high of €114.60 ($133.26). The company has a quick ratio of 7.40, a current ratio of 7.62 and a debt-to-equity ratio of 8.61. The company has a 50-day moving average price of €99.79 and a 200 day moving average price of €91.88. The company has a market cap of $3.44 billion and a PE ratio of -82.44.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Featured Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.